OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Traina on Treatment Considerations for HER2+ Breast Cancer

February 3rd 2018

Tiffany A. Traina, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, on considerations for the treatment of patients with HER2-positive breast cancer.

Dr. Taneja Discusses Multiparametric MRI in Prostate Cancer

February 3rd 2018

Samir Taneja, MD, James M. Neissa and Janet Riha Neissa professor of urologic oncology, vice chair, Department of Urology, professor, Department of Radiology, co-director, Smilow Comprehensive Prostate Cancer Center, director, Urologic Oncology, Genito-Urologic program leader, NYU Langone’s Perlmutter Cancer Center, discusses multiparametric MRI in prostate cancer.

Dr. Mason on Treatment Decisions Following 10-Year PROTECT Data in Prostate Cancer

February 1st 2018

Malcolm Mason, MD, Cancer Research Wales Professor of Clinical Oncology at Cardiff University, discusses how to determine a treatment strategy for patients with prostate cancer following the 10-year PROTECT study data.

Dr. Rogers on Benefits of Ibrutinib Combination in CLL

February 1st 2018

Kerry Rogers, MD, assistant professor, Internal Medicine, Division of Hematology, The Ohio State University Comprehensive Cancer Center, discusses the benefits of ibrutinib (Imbruvica) in combination with venetoclax (Venclexta) and obinutuzumab (Gazyva) for patients with chronic lymphocytic leukemia (CLL).

Dr. Gasparetto on Efficacy of Selinexor Combination in Multiple Myeloma

February 1st 2018

Cristina Gasparetto, MD, assistant professor of medicine, member of the Duke Cancer Institute, discuss the efficacy of selinexor in combination with dexamethasone for the treatment of patients with multiple myeloma.

Dr. Salgia on Importance of Molecular Markers in Lung Cancer

February 1st 2018

Ravi Salgia, MD, PhD, Arthur & Rosalie Kaplan Chair in Medical Oncology, associate director for clinical sciences at City of Hope, discusses the importance of molecular markers in lung cancer.

Dr. Morgan Discusses the Impact of PARP Inhibitors in Prostate Cancer

February 1st 2018

Alicia Morgan, MD, Mather Hospital, discusses the impact of PARP inhibitors in prostate cancer.

Dr. Singh Discusses the Future of Immunotherapy in GIST

February 1st 2018

Arun S. Singh, MD, associate professor, UCLA David Geffen School of Medicine, discusses the future of immunotherapy in gastrointestinal stromal tumors (GIST).

Dr. Jarnagin on Surgical Protocols for CRC That Have Spread Beyond the Liver

February 1st 2018

William R. Jarnagin, MD, FACS, chief, Hepatopancreatobiliary Service, Benno C. Schmidt Chair, Surgical Oncology, Memorial Sloan Kettering Cancer Center, discusses the surgical barriers in treating patients with colorectal cancer that has metastasized outside of the liver.

Dr. Francis Discusses the SOFT Trial for Breast Cancer

February 1st 2018

Prudence Francis, MD, Peter MacCallum Cancer Centre, discusses the SOFT trial for patients with breast cancer.

Dr. Kulke on Emerging Cabozantinib Data for NETs

February 1st 2018

Matthew H. Kulke, MD, Dana-Farber Cancer Institute, discusses the emerging data seen with cabozantinib (Cabometyx) for patients with neuroendocrine tumors (NETs).

Dr. Tam Discusses the DUO Trial for CLL

February 1st 2018

Constantine S. Tam, MD, associate professor, Peter MacCallum Cancer Centre, discusses, the randomized phase III DUO trial of duvelisib versus ofatumumab (Arzerra) in patients with relapsed/refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).

Dr. Sequist Distinguishes Osimertinib From Earlier NSCLC TKIs

February 1st 2018

Lecia V. Sequist, MD, associate professor of medicine, Harvard Medical School, Mary B. Saltonstall Chair, Oncology, Massachusetts General Hospital Center, discusses the tolerability of a new third-generation T790-specific inhibitor, osimertinib (Tagrisso).

Dr. Ramirez Discusses Treating Patients With NETs of the Lung

January 31st 2018

Robert Ramirez, DO, FACP, Ochsner Medical Center, discusses treating patients with neuroendocrine tumors (NETs) of the lung.

Dr. Koprivnikar Discusses FLT3 Inhibitors in Hematologic Malignancies

January 31st 2018

Jamie Koprivnikar, MD, medical oncologist, John Theurer Cancer Center, discusses FLT3 inhibitors in the treatment of hematologic malignancies.

Developing Treatment for Invasive Lobular Carcinoma

January 31st 2018

Steffi Oesterreich, PhD, professor and vice chair of Precision and Translational Pharmacology, University of Pittsburgh, discusses developing treatment for patients with invasive lobular carcinoma (ILC).

Dr. Raz on the Impact of the ALCHEMIST Trial on the Treatment of Patients With Lung Cancer

January 31st 2018

Dan J. Raz, MD, MAS, co-director, Lung Cancer and Thoracic Oncology Program, assistant professor, Division of Thoracic Surgery, Department of Surgery, City of Hope, discusses the subsets of the ALCHEMIST trial.

Dr. Kim on the Safety of Immune Checkpoint Inhibition in Surgical Patients With Lung Cancer

January 31st 2018

Jae Y. Kim, MD, chief, Division of Thoracic Surgery, Department of Surgery, assistant professor, Department of Surgery, City of Hope, discusses the use of immune checkpoint inhibitors in surgical patients with lung cancer.

Dr. Bardia on Sacituzumab Govitecan in Triple-Negative Breast Cancer

January 31st 2018

Aditya Bardia, MD, MPH, assistant professor of medicine, Harvard Medical School, attending physician, Medical Oncology, Massachusetts General Hospital, discusses a trial investigating sacituzumab govitecan for patients with triple-negative breast cancer (TNBC).

Dr. Oh on Abiraterone Versus Docetaxel in Prostate Cancer

January 31st 2018

William K. Oh, MD, chief, Division of Hematology and Medical Oncology, professor of medicine and urology, Mount Sinai Hospital, discusses the abiraterone acetate (Zytiga) versus docetaxel for patients with prostate cancer.